250 related articles for article (PubMed ID: 15202100)
1. Positron emission imaging of head and neck cancer, including thyroid carcinoma.
Schöder H; Yeung HW
Semin Nucl Med; 2004 Jul; 34(3):180-97. PubMed ID: 15202100
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET in head and neck, and thyroid cancer.
Macapinlac HA
Chang Gung Med J; 2005 May; 28(5):284-95. PubMed ID: 16086543
[TBL] [Abstract][Full Text] [Related]
3. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
4. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma.
Goshen E; Cohen O; Rotenberg G; Oksman Y; Karasik A; Zwas ST
Nucl Med Commun; 2003 Sep; 24(9):959-61. PubMed ID: 12960594
[TBL] [Abstract][Full Text] [Related]
5. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
[TBL] [Abstract][Full Text] [Related]
7. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
Pai M; Park CH; Suh JH; Koh JH
Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.
Wong WL; Chevretton EB; McGurk M; Hussain K; Davis J; Beaney R; Baddeley H; Tierney P; Maisey M
Clin Otolaryngol Allied Sci; 1997 Jun; 22(3):209-14. PubMed ID: 9222623
[TBL] [Abstract][Full Text] [Related]
11. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer.
Hanasono MM; Kunda LD; Segall GM; Ku GH; Terris DJ
Laryngoscope; 1999 Jun; 109(6):880-5. PubMed ID: 10369275
[TBL] [Abstract][Full Text] [Related]
12. PET/CT imaging in recurrent head and neck cancer.
Fukui MB; Blodgett TM; Meltzer CC
Semin Ultrasound CT MR; 2003 Jun; 24(3):157-63. PubMed ID: 12877412
[TBL] [Abstract][Full Text] [Related]
13. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
14. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma.
Chen YK; Liu FY; Yen RF; Kao CH
Acad Radiol; 2003 Aug; 10(8):835-9. PubMed ID: 12945916
[TBL] [Abstract][Full Text] [Related]
15. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
16. Investigation of thyroid, head, and neck cancers with PET.
Zhuang H; Kumar R; Mandel S; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1101-11, viii. PubMed ID: 15488560
[TBL] [Abstract][Full Text] [Related]
17. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
18. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer).
Seo YL; Yoon DY; Baek S; Ku YJ; Rho YS; Chung EJ; Koh SH
Eur Radiol; 2012 Oct; 22(10):2246-54. PubMed ID: 22562091
[TBL] [Abstract][Full Text] [Related]
19. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
20. FDG PET in head and neck cancer.
Keyes JW; Watson NE; Williams DW; Greven KM; McGuirt WF
AJR Am J Roentgenol; 1997 Dec; 169(6):1663-9. PubMed ID: 9393187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]